Table 1.
Antiproliferative activity of DBPR114 in human HCC cell lines in vitro
| Cell line | Histopathology | Growth inhibition, IC50 (μM) | |
|---|---|---|---|
| DBPR114 | Sorafenib | ||
| HA22T/VGH | HCC, p53MT, poorly differentiated, HBV+/HCV− | 0.7 | 8.6 |
| HA59T/VGH | HCC, p53MT, poorly differentiated, HBV+/HCV− | 1.7 | 8.3 |
| Huh1 | HCC, p53MT, moderately differentiated, HBV−/HCV− | 1.9 | 9.5 |
| Huh7 | HCC, p53MT, moderately differentiated, HBV−/HCV− | 1.7 | 8.4 |
| PLC/PRF/5 | HCC, p53MT, moderately differentiated, HBV+/HCV− | 2.1 | 6.5 |
| Hep3B | HCC, p53null, well differentiated, HBV+/HCV− | 1.5 | 6.6 |
HCC cells were treated with DBPR114 or sorafenib at various concentrations for 72 h. Cell viability was assessed through WST-8 cell proliferation assay. IC50 values represent the mean of two independent experiments with eight concentrations and six replicates per concentration
p53null: p53 Deletion; p53MT : Mutant-type p53; HBV+ : Hepatitis B-positive virus; HBV−: Hepatitis B-negative virus; HCV− -: Hepatitis C-negative virus